Johnson & Johnson vs Merck & Co

Johnson & Johnson (JNJ), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Johnson & Johnson is worth $675.5B on the stock market and Merck & Co $354.4B: Johnson & Johnson is valued at 91% more. Johnson & Johnson trades at 42.6 times earnings and Merck & Co at 145. Over the past year Johnson & Johnson's share price has moved +41.3% and Merck & Co's +49.8%.

Key facts

Johnson & Johnson market value
$675.5B
Merck & Co market value
$354.4B
Johnson & Johnson P/E
42.6
Merck & Co P/E
145
Johnson & Johnson revenue
$94.2BFY to 2025-12-28
Merck & Co revenue
$65BFY to 2025-12-31
Superinvestors holding both
13

Market values as of .

Johnson & Johnson vs Merck & Co: every measure side by side
Measure Johnson & Johnson Merck & Co
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-282025-12-31
Size
Market cap$675.5Bhigher$354.4Blower
Revenue$94.2Bhigher$65Blower
Earnings$26.8Bhigher$18.3Blower
Employees138,200higher73,000lower
Total assets$199.2Bhigher$136.9Blower
Valuation
P/E42.6lower145higher
P/S7.2higher5.5lower
P/B8.3higher7.9lower
Dividend yield1.87%lower2.33%higher
Profitability
Operating margin——
Balance sheet
Net assets$81.5Bhigher$52.6Blower
Total liabilities$117.7Bhigher$84.2Blower
Total debt$47.9Blower$49.3Bhigher
Cash on hand$19.7Bhigher$14.6Blower
Price change
Today-0.68%lower-0.48%higher
1 year+41.3%lower+49.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Merck & Co). Who owns JNJ · Who owns MRK

Further comparisons

Learn

Questions and answers

Which is bigger, Johnson & Johnson or Merck & Co?

By market value, Johnson & Johnson is the larger: $675.5B against $354.4B for Merck & Co. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $65B for Merck & Co.

Which has the higher P/E ratio?

Merck & Co: 145, against 42.6 for Johnson & Johnson. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Merck & Co: 2.33%, against 1.87% for Johnson & Johnson. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Merck & Co: $49.3B, against $47.9B for Johnson & Johnson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Johnson & Johnson and Merck & Co?

In their latest 13F filings, Jeremy Grantham (co-founder), Mark Boyar, Ken Fisher, Mairs & Power team, Charles Brandes (founder), Cliff Asness, Ken Griffin, Murray Stahl, Christopher Bloomstran, Howard Gleicher, Rajiv Jain, Dodge & Cox team and Thomas Russo hold both.

Cite this page

Funkfolio, “Johnson & Johnson vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/jnj-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.